Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatmentThe effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocolEvaluation of foldable intraocular lenses in patients with uveitis.Ocular manifestations of systemic lupus erythematosus.Sub-tenon's block: a national United Kingdom survey.Trabeculectomy with mitomycin C in refractory glaucoma associated with nonnecrotizing anterior scleritis.T-lymphocyte subpopulations in uveitisDoes trabeculectomy influence the course of uveitis?Changing patterns of HIV related ocular disease.Long-term follow-up of trabeculectomy without antimetabolites in patients with uveitis.Behçet's syndrome: a multidisciplinary approach to clinical care.Tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review of its epidemiology, demographics and risk factors.An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Pharmacotherapy for uveitis: current management and emerging therapy.Heparin surface modified intraocular lenses in uveitis.ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.Behçet's disease: ocular effects and treatment.Primary anti-phospholipid antibody syndrome (APS): current concepts.Clinical course and visual outcome in patients with diabetes mellitus and uveitis.Long-term biocompatibility and visual outcomes of a hydrophilic acrylic intraocular lens in patients with uveitis.Cortisol biosynthesis in the human ocular surface innate immune response.Degree, duration, and causes of visual loss in uveitis.Unregistered visual impairment: is registration a failing system?The role of chemokines and their receptors in ocular disease.Uveitis: a potentially blinding disease.Objective measurement of vitreous inflammation using optical coherence tomography.Birmingham Behçet's service: classification of disease and application of the 2014 International Criteria for Behçet's Disease (ICBD) to a UK cohortAdalimumab for sight-threatening uveitis in Behçet's disease.Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management.Inflammatory mediators of uveitis: cytokines and chemokines.Ocular hypertension associated with ocular sarcoidosis.International Uveitis Study Group (IUSG): clinical classification of uveitis.Fuchs' heterochromic uveitis and sarcoidosis.Evidence-based practice in Behçet's disease: identifying areas of unmet need for 2014.Systemic treatment of sarcoidosis.Understanding uveitis: the impact of research on visual outcomes.Diffuse large B-cell lymphoma: the history, current view and new perspectives.Systemic lupus erythematosus: An update for ophthalmologists."The patient is speaking": discovering the patient voice in ophthalmology.Do Demographic Factors Influence Uveitis Patients' Understanding of Uveitis?
P50
Q26749730-1EA3AC74-7016-4F40-9B1C-663873144C8CQ28068067-97E34954-8985-4FA5-963D-E2781E46D5C2Q33180368-B19B8641-9793-49C9-8E3A-1214CBCA6337Q33293337-413978F2-7124-4446-BB62-A503B516D68EQ33373439-A1692CBB-67E4-44F6-BA01-11A73B8139EFQ33517759-53E32F4F-6616-47CE-A2AD-3272ADF1A4A3Q33643603-9DC435D7-B7EC-4756-85A4-2B354F36B1D6Q33695968-045679DC-7601-4161-902D-4AB61E5DF0F8Q33711640-B52294DE-1941-4136-8D09-58D468564CDAQ33782109-F2A40820-56A9-4516-BC16-2429BE1F5016Q33784395-1107F5B8-5EAB-44A5-A614-2C8461CD1DC2Q33910485-4D009ABE-B308-42C0-A005-EC1E58146415Q33910781-0A08257D-11CC-4CB8-BA75-1DA625566C69Q34274075-7A99BDDA-2F56-44BB-AE34-65341351C6A5Q34347894-248DD244-0081-4DCD-8FD5-397B30C38888Q34522758-16274ABB-25F9-435B-873F-D4F85A9607E9Q34585314-C8A541F0-04A3-4C16-948A-5A4A411F476FQ34674429-B391278A-9AEA-4455-8664-B3E3E9D2CE6AQ34694705-4D5480EC-CA06-44B8-9016-027F5DC866F4Q35105041-6DFE4837-353C-4E7B-8D40-1011C34986B1Q35149219-58245D72-0075-4600-B321-50BA33147CD8Q35592376-2EA148F0-4ECA-4982-A0C1-B28E64E8D707Q35593495-50361576-69E0-4ADC-973D-CB910C43CA49Q35818754-9C361D60-DC4B-4AEC-A18B-1E4CCBBCDCFEQ35838711-9EA71630-C5CD-47E4-8E7B-87A789186D9BQ35866363-E0EA2AFD-7736-4C49-A3CD-616CC73437ACQ36304764-974550DC-A9DE-4CA3-8DCC-7A849CDC12C4Q36443513-2353332E-1A82-4EF9-8ED5-797D9C9BCDF2Q36575740-B7E91B5F-6115-4E39-92EF-A6EA335ECB3AQ36634978-DF58EB40-DCFF-4257-B0AE-EB4A74D01EEBQ37034323-135E22A2-AED4-458C-9748-B68A8E6AE158Q37124620-8EB340E0-4F75-4182-AB09-76F963306AC8Q37316368-81B967D2-BF32-4DBF-825F-96ED9037E8D1Q37539557-CBB0C797-5340-442E-8E8D-28D0A7E76018Q37856272-3FAB1061-C3B5-4B88-8F43-A402A2F2D969Q37909585-87D14E7B-6EA2-4570-897A-96630D7ECEEDQ38230248-5E737731-5624-4E0F-9B05-5C790BE3CF59Q38551536-3B3350A9-631D-4071-BD83-D715D3CF7C97Q38689548-2F38A82B-D232-4FBC-B905-FA17BEEAA0A6Q38845485-012AB8A4-5F62-4503-ABCB-57D47052CD4A
P50
description
Brits onderzoeker
@nl
Professor of Ophthalmology and Consultant Ophthalmologist
@en
Professor of Ophthalmology and Consultant Ophthalmologist
@en-gb
investigador británico
@es
investigador británicu
@ast
name
Philip I Murray
@sl
Philip I. Murray
@af
Philip I. Murray
@an
Philip I. Murray
@ast
Philip I. Murray
@bar
Philip I. Murray
@br
Philip I. Murray
@ca
Philip I. Murray
@co
Philip I. Murray
@cs
Philip I. Murray
@cy
type
label
Philip I Murray
@sl
Philip I. Murray
@af
Philip I. Murray
@an
Philip I. Murray
@ast
Philip I. Murray
@bar
Philip I. Murray
@br
Philip I. Murray
@ca
Philip I. Murray
@co
Philip I. Murray
@cs
Philip I. Murray
@cy
altLabel
PI Murray
@en
PI Murray
@en-gb
Phil Murray
@en
Phil Murray
@en-gb
Philip Murray
@af
Philip Murray
@an
Philip Murray
@ast
Philip Murray
@bar
Philip Murray
@br
Philip Murray
@ca
prefLabel
Philip I Murray
@sl
Philip I. Murray
@af
Philip I. Murray
@an
Philip I. Murray
@ast
Philip I. Murray
@bar
Philip I. Murray
@br
Philip I. Murray
@ca
Philip I. Murray
@co
Philip I. Murray
@cs
Philip I. Murray
@cy
P1006
P1015
P214
P244
P269
P1006
P1015
P1153
35595791500
P1207
n2006076078
P1695
P2013
philip.i.murray
P21
P213
0000 0001 1720 071X